Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04746209 · ClinicalTrials.gov registry record · Phase 2
Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
A Phase 2 study of B-cell Acute Lymphoblastic Leukemia and B-cell Childhood Acute Lymphoblastic Leukemia, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04746209 is a Phase 2 study of B-cell Acute Lymphoblastic Leukemia and B-cell Childhood Acute Lymphoblastic Leukemia that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 25 participants, below the 88-participant average among 21 other B-cell Acute Lymphoblastic Leukemia trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04746209, a Phase 2 study of B-cell Acute Lymphoblastic Leukemia and B-cell Childhood Acute Lymphoblastic Leukemia, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic hematopoietic cell transplantation (HCT) followed by blinatumomab therapy for high-risk B cell acute lymphoblastic leukemia (ALL) as a means of reducing rates of subsequent relapse and improving survival, while also minimizing treatment-related morbidity/ mortality and late effects. The conditioning regimens will be dependent on the patient's minimal residual disease (MRD) status prior to HCT using high throughput sequencing.
Conditions Studied
Interventions
- DRUG Blinatumomab
- DEVICE Alpha/Beta T-cell and B-cell depleted HCT
Study Locations (1)
Wisconsin
- Children's Hospital of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04746209
The ClinicalTrials.gov registry entry for NCT04746209 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 88-participant average among 21 other B-cell Acute Lymphoblastic Leukemia trials with a reported enrollment target (72% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with B-cell Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Blinatumomab is the first listed.
NCT04746209 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04746209 about?
NCT04746209 is a clinical study titled "Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT". This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic hematopoietic cell transplantation (HCT) followed by blinatumomab therapy for high-risk B cell acute lymphoblastic leukemia (ALL) as a means of reducing rates of subsequent relapse and improving survival, whil...
What is the current status of trial NCT04746209?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-02-01. Estimated completion is 2029-12-31.
What conditions does trial NCT04746209 study?
This clinical trial studies the following conditions: B-cell Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-Cell ALL, Childhood.
What interventions are being tested in trial NCT04746209?
The interventions under investigation include: Blinatumomab (DRUG), Alpha/Beta T-cell and B-cell depleted HCT (DEVICE).
Who is sponsoring clinical trial NCT04746209?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04746209 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
RECRUITING · Phase 2
-
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
RECRUITING · Phase 2
-
A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
ACTIVE NOT RECRUITING · Phase 2
-
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
B-cell Acute Lymphoblastic Leukemia
All registered trials for this condition
B-cell Childhood Acute Lymphoblastic Leukemia
All registered trials for this condition
Wisconsin
All trials with a study site in Wisconsin
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.